Patient Experience in Treatment for Low-grade Upper Tract Urothelial Carcinoma

Overview

About this study

to identify, describe, and substantiate important and relevant concepts related to (1) the signs, symptoms, and impacts of Low grade upper tract urothelial carcinoma (LG UTUC); (2) treatment burden and patients’ current treatment experiences for LG UTUC; and (3) perceptions of UGN-101, a novel topical chemotherapy for LG UTUC treatment, from the perspective of US-based adults with LG UTUC.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

• Study participant is ≥18 years of age;

• Study participant has completed a written ICF and HIPAA Authorization;

• Study participant has clinician-confirmed diagnosis of naïve or recurrent low-grade UTUC via endoscopic biopsy (or has previously had a clinically confirmed diagnosis of LG UTUC before surgical treatment with radical nephroureterectomy);

• Study participant has experience with at least one of three treatments: (1) UGN-101, and/or (2) endoscopic management (defined as undergoing at least one endoscopic tumor resection in additional to the diagnostic resection), and/or (3) radical nephroureterectomy (RNU);

• Study participant is fluent in US English (i.e., able to speak, read, write, and comprehend); and

• Study participant is willing and able to participate in a 60-minute, audio-recorded telephone interview

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Raymond Pak, M.D., M.B.A.

Closed for enrollment

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mitchell Humphreys, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions